Targeting methylation-modifying enzymes, such as METTL3, METTL4, and DNMT1, provides a promising therapeutic strategy to regulate gene expression, alleviate AEC dysfunction, and slow the progression of bacterial Sepsis-Associated ALI. This evidence concerns the gene METTL3 and bacterial infectious disease with sepsis.